Arcutis anticipates net product revenue of between $455 million and $470 million for the full year 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Is ARQT a Buy, Before Earnings?
- Arcutis Biotherapeutics presents quality of life, long-term data on ZORYVE
- Arcutis Biotherapeutics: Buy Rating Affirmed Amid FDA Approval and Strategic Growth Initiatives
- Arcutis Biotherapeutics announces FDA approval of ZORYVE cream sNDA
- Arcutis Biotherapeutics announces new Zoryve data at EADV congress